(A)

(B)

HBV-HCC Public HCV-HCC Recurrence Tumorigenesis Tumorigenesis Recurrence Error rate <0.1 P<0.01 P<0.01 Error rate <0.1 20 12 126 38 26 58

Figure S7. Comparison of recurrence-associated and tumorigenic pathways. Recurrence-associated pathways identified in the present study were compared with those associated with tumorigenesis in HCC obtained from our prior analysis of the same public HBV and HCC datasets [12]. In total, (A) 64 recurrence-associated pathways from our HBV-HCC dataset (log-rank p-value<0.01 in the test set) were compared with 84 tumorigenic pathways from another HBV-positive HCC dataset (error rate<0.1), and (B) 32 recurrence-associated pathways from public HCV-HCC (log-rank p-value<0.01 in the test set) compared with 138 tumorigenic pathways from the same dataset (error rate<0.1).